Get the Stockscreener App
17.60
6.03%
-1.13
After Hours:
17.60
Arrivent Biopharma Inc stock is traded at $17.60, with a volume of 440.45K.
It is down -6.03% in the last 24 hours and down -11.29% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$18.73
Open:
$18.38
24h Volume:
440.45K
Relative Volume:
1.37
Market Cap:
$714.01M
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-4.3781
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
-9.70%
1M Performance:
-11.29%
6M Performance:
-17.37%
1Y Performance:
-42.82%
1-Day Range:
$17.00
$18.50
1-Week Range:
$17.00
$20.04
52-Week Range:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
17.60 | 759.86M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Will ArriVent BioPharma Inc. stock gain from lower inflationJuly 2025 Summary & Daily Price Action Insights - newser.com
Why ArriVent BioPharma Inc. stock could benefit from AI revolution2025 Market Overview & Weekly High Potential Stock Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with risk reward ratio charts2025 Market Trends & Verified Entry Point Signals - newser.com
Evaluating ArriVent BioPharma Inc. with trendline analysisJuly 2025 Momentum & Expert Curated Trade Setup Alerts - newser.com
Why ArriVent BioPharma Inc. stock is favored by pension funds2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Best data tools to analyze ArriVent BioPharma Inc. stock2025 Retail Activity & Low Drawdown Investment Strategies - newser.com
Multi asset correlation models including ArriVent BioPharma Inc.Weekly Stock Summary & Safe Entry Zone Identification - newser.com
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Published on: 2025-11-02 12:15:30 - newser.com
Is ArriVent BioPharma Inc. stock a defensive play in 2025Portfolio Risk Summary & Pattern Based Trade Signal System - newser.com
Real time pattern detection on ArriVent BioPharma Inc. stockMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Moody Aldrich Partners LLC Takes $1.56 Million Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Why retail investors pile into ArriVent BioPharma Inc. stockJuly 2025 Outlook & Free Technical Pattern Based Buy Signals - newser.com
Is ArriVent BioPharma Inc a good long term investmentEarnings Surprise Analysis & High Profit Trading Alerts - earlytimes.in
ArriVent BioPharma’s Phase 3 Study on Firmonertinib: A Potential Game-Changer in NSCLC Treatment - TipRanks
Momentum divergence signals in ArriVent BioPharma Inc. chartBull Run & Daily Risk Controlled Trade Plans - newser.com
What is the fair value of ArriVent BioPharma Inc. stock nowPortfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Is ArriVent BioPharma Inc. meeting your algorithmic filter criteriaPortfolio Performance Report & Real-Time Stock Movement Alerts - newser.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is ArriVent BioPharma Inc. stock in correction or buying zoneQuarterly Profit Review & Low Drawdown Momentum Trade Ideas - newser.com
Published on: 2025-10-28 03:24:22 - newser.com
Why ArriVent BioPharma Inc. stock remains a top recommendationJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - fcp.pa.gov.br
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):